NCT03538171
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Misc Inhibitor, Endocrine (Hormone) Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with previous or current metastatic foci in central nervous system, or leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03538171